Aura Biosciences, Inc.
AURA · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | $0 | -$0 |
| % Margin | – | – | – | – |
| R&D Expenses | $22 | $23 | $23 | $22 |
| G&A Expenses | $0 | $6 | $6 | $0 |
| SG&A Expenses | $5 | $6 | $6 | $5 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$0 | $0 | $0 |
| Operating Expenses | $28 | $28 | $29 | $28 |
| Operating Income | -$28 | -$29 | -$29 | -$28 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $2 | $2 | $2 | $2 |
| Pre-Tax Income | -$26 | -$27 | -$27 | -$26 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$26 | -$27 | -$27 | -$26 |
| % Margin | – | – | – | – |
| EPS | -0.4 | -0.47 | -0.55 | -0.52 |
| % Growth | 14.9% | 14.5% | -5.8% | – |
| EPS Diluted | -0.4 | -0.47 | -0.55 | -0.52 |
| Weighted Avg Shares Out | 66 | 58 | 50 | 50 |
| Weighted Avg Shares Out Dil | 66 | 58 | 50 | 50 |
| Supplemental Information | – | – | – | – |
| Interest Income | $2 | $2 | $2 | $2 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$26 | -$27 | -$29 | -$26 |
| % Margin | – | – | – | – |